General malaise; This non-serious case was reported by a consumer via sales rep and described the occurrence of general malaise in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 11-JAN-2025, the patient received the 1st dose of Shingrix (left arm). On 12-JAN-2025, 1 days after receiving Shingrix, the patient experienced general malaise (Verbatim: General malaise). On 13-JAN-2025, the outcome of the general malaise was resolved (duration 1 day). The reporter considered the general malaise to be related to Shingrix. The company considered the general malaise to be related to Shingrix. Additional Information: GSK Receipt Date: 15-JAN-2025 The reporter reported that the patient received receive first dose of Shingrix. The patient had general malaise.